Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Breast Neoplasms 1Blast Crisis 1Anemia 1

Interventions

Cyclophosphamide 10fludarabine 8Mycophenolic Acid 7Tacrolimus 6Melphalan 6ruxolitinib 5fludarabine phosphate 5Imatinib Mesylate 5Busulfan 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Azacitidine 4nilotinib 3Whole-Body Irradiation 3Thiotepa 3Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3lintuzumab 2Vorinostat 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2Filgrastim 2Alemtuzumab 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Erlotinib Hydrochloride × Myeloid × Clear all
NCT00977548 2013-09-16

Erlotinib Study for Myelodysplastic Syndrome (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 10 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡